
Elvire Pons-Tostivint

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9325474/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-sma cell lung cancer patients treated with first-line pembrolizumab. Cancer Immunology, Immunotherapy, 2022, 71, 1747-1756.	 2.0	5
2	HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. Current Oncology, 2022, 29, 3748-3758.	0.9	7
3	STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact. Cells, 2021, 10, 3129.	1.8	30
4	Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis. Radiotherapy and Oncology, 2020, 145, 109-116.	0.3	26
5	Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis. Annals of Surgical Oncology, 2019, 26, 356-365.	0.7	47